Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study

Katsuhiro Ito, Yuki Kita, Akira Yokomizo, Jun Miki, Yuko Yoshio, Hiroaki Matsumoto, Takehiko Segawa, Takashi Karashima, Naotaka Nishiyama, Kazuto Imai, Shigetaka Suekane, Seiji Nagasawa, Shin Higashi, Hiroyuki Nishiyama, Hiroshi Kitamura, Takashi Kobayashi*

*この論文の責任著者

研究成果: ジャーナルへの寄稿学術論文査読

7 被引用数 (Scopus)

抄録

Pembrolizumab, an anti-programmed death 1 monoclonal antibody, has revolutionized the treatment of metastatic urothelial carcinoma. However, the optimal treatment duration for treatment responders has not been established. To address this, we retrospectively assess the treatment outcomes and duration of pembrolizumab for patients whose best response was complete response (CR) or partial response (PR) in a Japanese nationwide cohort of platinum-refractory metastatic urothelial carcinoma. Of 203 patients whose best response was CR or PR, 83 patients discontinued pembrolizumab before progression. The median pembrolizumab treatment duration was 6.9 months. The 2-year relapse-free survival (RFS), treatment-free survival, and OS rates after discontinuation were 49.0%, 57.4%, and 74.5%, respectively. CR, higher hemoglobin levels, and a better Eastern Cooperative Oncology Group performance status at the time of discontinuation were associated with significantly better RFS. Pembrolizumab was re-administered to 12 patients. Pembrolizumab re-challenge resulted in CR, PR, stable disease, and progressive disease in six, three, two, and one patient, respectively. Propensity score-matched landmark analysis revealed no significant OS difference between patients who continued or discontinued pembrolizumab at 6, 12, and 18 months (p = 0.91, 0.99, and 0.25, respectively). Our findings demonstrated that patients with objective responses had favorable survival outcomes and suggested that pembrolizumab could be discontinued safely in this population. This study should drive further efforts to optimize the treatment duration for pembrolizumab responders.

本文言語英語
ページ(範囲)2325-2332
ページ数8
ジャーナルCancer Medicine
12
3
DOI
出版ステータス出版済み - 2023/02

ASJC Scopus 主題領域

  • 腫瘍学
  • 放射線学、核医学およびイメージング
  • 癌研究

フィンガープリント

「Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル